CALITHERA BIOSCIENCES INC (CALA) Stock Price, Forecast & Analysis
USA - NASDAQ:CALA - US13089P5070 - Common Stock
CALA Key Statistics, Chart & Performance
The current stock price of CALA is 0.3651 USD. In the past month the price decreased by -88.15%. In the past year, price decreased by -96.7%.
CALA Latest News, Press Relases and Analysis
CALA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.28 | 405.34B | ||
| AMGN | AMGEN INC | 15.37 | 180.93B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.33 | 108.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.37 | 78.11B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 874.1 | 58.43B | ||
| INSM | INSMED INC | N/A | 42.20B | ||
| NTRA | NATERA INC | N/A | 30.96B | ||
| BIIB | BIOGEN INC | 10.05 | 24.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.47B | ||
| INCY | INCYTE CORP | 15.85 | 19.87B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.06B |
Related stock screener links
About CALA
Company Profile
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The firm is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The firm is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The firm's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
Company Info
CALITHERA BIOSCIENCES INC
343 Oyster Point Blvd #200
South San Francisco CALIFORNIA 94080 US
CEO: Susan M. Molineaux
Employees: 63
Phone: 16508701000.0
CALITHERA BIOSCIENCES INC / CALA FAQ
What does CALA do?
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The firm is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The firm is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The firm's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
Can you provide the latest stock price for CALITHERA BIOSCIENCES INC?
The current stock price of CALA is 0.3651 USD. The price decreased by -10.95% in the last trading session.
Does CALITHERA BIOSCIENCES INC pay dividends?
CALA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CALA stock?
CALA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for CALITHERA BIOSCIENCES INC?
The Revenue of CALITHERA BIOSCIENCES INC (CALA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does CALITHERA BIOSCIENCES INC (CALA) report earnings?
CALITHERA BIOSCIENCES INC (CALA) will report earnings on 2023-03-29, after the market close.
What is the ownership structure of CALITHERA BIOSCIENCES INC (CALA)?
You can find the ownership structure of CALITHERA BIOSCIENCES INC (CALA) on the Ownership tab.
CALA Technical Analysis
CALA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CALA. CALA may be in some trouble as it scores bad on both profitability and health.
CALA Financial Highlights
Over the last trailing twelve months CALA reported a non-GAAP Earnings per Share(EPS) of -12. The EPS increased by 36.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CALA Forecast & Estimates
10 analysts have analysed CALA and the average price target is 5.1 USD. This implies a price increase of 1296.88% is expected in the next year compared to the current price of 0.3651.
For the next year, analysts expect an EPS growth of 69.34% and a revenue growth -100% for CALA